Akineton (Biperiden)
Anticholinergic injection for Parkinson's disease and drug-induced movement disorders
Quick facts about Akineton
Key takeaways about Akineton
- Used for movement disorders: Akineton treats Parkinson's disease symptoms and drug-induced extrapyramidal reactions, particularly acute dystonia caused by antipsychotic medications
- Rapid-acting injection: When given intravenously, the effect is nearly immediate; intramuscular injection takes effect within 10-30 minutes
- Not for tardive dyskinesia: Akineton must not be used to treat tardive dyskinesia, as it may worsen this condition
- Caution in elderly patients: Older adults are more sensitive to anticholinergic effects and may require lower doses
- Avoid alcohol: Alcohol should be avoided during Akineton treatment as it can increase central nervous system side effects
What Is Akineton and What Is It Used For?
Akineton (biperiden) is an anticholinergic medication used to treat Parkinson's disease and drug-induced extrapyramidal symptoms. It is available as a 5 mg/ml injection solution and works by blocking muscarinic acetylcholine receptors in the brain, restoring the balance between dopamine and acetylcholine in the basal ganglia.
Akineton belongs to a class of medications known as anticholinergic (antimuscarinic) agents. Its active substance, biperiden lactate, acts primarily on muscarinic M1 receptors in the central nervous system. By blocking these receptors, biperiden helps to reduce the overactivity of cholinergic pathways that occurs when dopaminergic transmission is impaired, as in Parkinson's disease.
The medication is available as an injectable solution (5 mg/ml) and is administered either intramuscularly or by slow intravenous injection. This parenteral formulation is particularly valuable in clinical settings where rapid control of symptoms is required, such as in acute dystonic reactions caused by antipsychotic medications.
Akineton is used in two primary clinical contexts. First, it serves as an adjunctive treatment for Parkinson's disease, where it can help manage tremor, rigidity, and other motor symptoms. Anticholinergic medications were among the first drugs used to treat Parkinson's disease, and while they have largely been supplemented by more targeted therapies like levodopa and dopamine agonists, they remain useful for certain patients, particularly those with prominent tremor.
Second, and perhaps more commonly in modern clinical practice, Akineton is used to treat drug-induced extrapyramidal symptoms. These are movement disorders that can occur as a side effect of various medications, most notably antipsychotic drugs (neuroleptics). Extrapyramidal symptoms include acute dystonia (sudden, sustained muscle contractions), akathisia (restlessness), parkinsonism (tremor, rigidity, bradykinesia), and initial dyskinesia (involuntary movements). Akineton injection is especially effective for treating acute dystonic reactions, which can be distressing and potentially dangerous if they involve the muscles of the throat or respiratory system.
In normal brain function, there is a delicate balance between dopamine and acetylcholine signaling in the basal ganglia. In Parkinson's disease or when antipsychotic drugs block dopamine receptors, this balance shifts toward excessive cholinergic activity. Akineton restores this balance by blocking muscarinic acetylcholine receptors, thereby reducing the relative excess of cholinergic signaling.
Key indications for Akineton injection
- Parkinson's disease: As adjunctive therapy for motor symptoms, particularly tremor
- Acute dystonia: Sudden involuntary muscle contractions caused by antipsychotic or other dopamine-blocking medications
- Initial dyskinesia: Early-onset involuntary movements associated with drug therapy
- Drug-induced parkinsonism: Parkinsonian symptoms caused by medications, especially antipsychotics
What Should You Know Before Taking Akineton?
Before receiving Akineton, inform your healthcare provider about all medical conditions, particularly gastrointestinal narrowing, glaucoma, prostatic hyperplasia, seizure disorders, or heart rhythm problems. Akineton must not be used in patients with gastrointestinal stenosis, risk of acute angle-closure glaucoma, or tardive dyskinesia.
Akineton is a powerful anticholinergic medication, and its safety profile must be carefully considered before administration. Your healthcare provider will evaluate whether Akineton is appropriate for you based on your medical history, current medications, and overall health status. It is essential that you provide complete information about your health to ensure safe treatment.
Like all anticholinergic drugs, Akineton can affect multiple organ systems beyond the central nervous system. It can reduce gastrointestinal motility, decrease secretions (including saliva, sweat, and digestive juices), increase heart rate, raise intraocular pressure, and cause urinary retention. These effects are generally manageable in most patients but can be problematic in certain medical conditions.
Contraindications
You must not receive Akineton if you have any of the following conditions:
- Allergy to biperiden lactate or any other ingredient in the formulation
- Gastrointestinal stenosis (narrowing of the digestive tract), as anticholinergic effects may worsen obstruction
- Risk of acute angle-closure glaucoma, since anticholinergic agents can increase intraocular pressure and precipitate an acute attack
- Tardive dyskinesia (delayed-onset involuntary movements), as Akineton does not treat this condition and may worsen it
It is critical to distinguish between tardive dyskinesia and acute dystonia before administering Akineton. While acute dystonia responds well to anticholinergic treatment, tardive dyskinesia can be worsened by anticholinergic agents. Tardive dyskinesia typically develops after prolonged use of antipsychotic medications and presents with repetitive, involuntary movements of the face, tongue, and extremities.
Warnings and Precautions
Special caution is required when using Akineton in the following situations:
- Prostatic hyperplasia (enlarged prostate): Anticholinergic effects may worsen urinary retention. Dose reduction may be necessary if difficulty urinating occurs.
- Increased seizure susceptibility: Biperiden may lower the seizure threshold in patients with epilepsy or other seizure disorders.
- Tachycardia (rapid heart rate): Anticholinergic agents can increase heart rate, which may be problematic in patients with pre-existing cardiac conditions.
- Elderly patients: Older adults are generally more sensitive to anticholinergic effects, including cognitive impairment, confusion, urinary retention, and constipation. Lower doses may be required.
Healthcare providers should monitor patients carefully during treatment, particularly during dose adjustments. Anticholinergic medications can impair cognitive function, especially in elderly patients, and may increase the risk of falls due to dizziness or sedation.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, inform your healthcare provider before receiving Akineton. There is limited clinical experience with biperiden use during pregnancy, and the potential risks to the developing fetus have not been fully established. Your healthcare provider will weigh the benefits of treatment against the potential risks.
Biperiden passes into breast milk and may affect the nursing infant. Due to the potential for anticholinergic effects in the breastfed baby, breastfeeding is not recommended during Akineton treatment. If you are breastfeeding and require treatment with Akineton, discuss alternative feeding options with your healthcare provider.
Driving and Operating Machinery
Akineton may reduce your reaction time and affect your ability to drive or operate machinery. Side effects such as drowsiness, dizziness, and blurred vision can impair alertness and coordination. You should not drive or use dangerous machinery until you know how Akineton affects you. Discuss with your healthcare provider if you have concerns about this.
Akineton injection contains less than 1 mmol (23 mg) sodium per ampoule, meaning it is essentially sodium-free. This is relevant for patients on sodium-restricted diets.
How Does Akineton Interact with Other Drugs?
Akineton interacts with other anticholinergic medications including antipsychotics, antihistamines, other antiparkinsonian drugs, antispasmodics, quinidine, and levodopa. Concurrent use can enhance anticholinergic side effects such as dry mouth, urinary retention, constipation, and confusion. Alcohol should be avoided during treatment.
Drug interactions with Akineton primarily arise from its anticholinergic mechanism of action. When combined with other drugs that have anticholinergic properties, the effects are additive or synergistic, meaning that side effects can become more pronounced and potentially dangerous. It is essential that your healthcare provider knows about all medications you are taking.
The most clinically significant interactions occur with medications that also block muscarinic acetylcholine receptors. When multiple anticholinergic drugs are used simultaneously, patients may experience severe dry mouth, constipation, urinary retention, tachycardia, blurred vision, cognitive impairment, and in extreme cases, anticholinergic toxicity with delirium and hallucinations.
| Drug Class | Examples | Effect | Severity |
|---|---|---|---|
| Antipsychotics (Neuroleptics) | Haloperidol, chlorpromazine, risperidone | Enhanced anticholinergic side effects; may reduce antipsychotic efficacy | Major |
| Antihistamines | Diphenhydramine, promethazine, hydroxyzine | Increased risk of drowsiness, dry mouth, urinary retention, constipation | Moderate |
| Other Antiparkinsonian drugs | Trihexyphenidyl, benztropine, procyclidine | Additive anticholinergic effects; increased risk of toxicity | Major |
| Antispasmodics | Hyoscine, oxybutynin, tolterodine | Enhanced peripheral anticholinergic effects (dry mouth, constipation, urinary retention) | Moderate |
| Quinidine | Quinidine sulfate | Enhanced anticholinergic cardiac effects; potential for increased heart rate | Moderate |
| Levodopa | Levodopa/carbidopa (Sinemet), levodopa/benserazide | May enhance or modify the effects of both drugs; careful dose adjustment needed | Moderate |
| Alcohol | All alcoholic beverages | Increased central nervous system depression; enhanced drowsiness and dizziness | Major |
Major Interactions
The most significant interactions involve other medications with strong anticholinergic properties. When Akineton is used together with antipsychotic medications, which is common since extrapyramidal symptoms are a side effect of antipsychotics, there is a risk of enhanced anticholinergic effects. This combination requires careful monitoring and dose optimization by a healthcare professional.
Concurrent use of multiple anticholinergic agents can lead to anticholinergic syndrome, characterized by confusion, hallucinations, agitation, tachycardia, fever, dry skin, dilated pupils, urinary retention, and reduced bowel sounds. This is a medical emergency requiring immediate attention.
Minor Interactions
Levodopa, a cornerstone treatment for Parkinson's disease, may have its effects modified when used together with Akineton. While the combination can be clinically beneficial for some patients, it requires careful dose adjustment by a neurologist. Biperiden may also reduce the absorption of certain medications by slowing gastrointestinal motility.
Patients should be advised to avoid alcohol completely during Akineton treatment. Alcohol enhances the central nervous system depressant effects of biperiden, increasing the risk of severe drowsiness, impaired coordination, and falls.
What Is the Correct Dosage of Akineton?
Akineton dosage is determined individually by a physician. For Parkinson's disease, 2-4 ampoules (10-20 mg) are given per day, divided over the day, intramuscularly or by slow intravenous injection. For acute dystonia, half to one ampoule (2.5-5 mg) is given, which may be repeated after 30 minutes if needed.
Akineton is always administered by a healthcare professional in a clinical setting. The injectable formulation is used when rapid onset of action is required or when oral administration is not feasible. Your doctor will determine the appropriate dose based on your specific condition, the severity of symptoms, and your response to treatment.
The medication can be given via two routes: intramuscular injection (into a muscle) or slow intravenous injection (directly into a vein). The intravenous route provides the fastest onset of action, which is particularly important in acute dystonic reactions where symptoms may be severe and distressing.
| Indication | Dose | Route | Notes |
|---|---|---|---|
| Parkinson's disease (severe cases) | 2-4 ampoules (10-20 mg) per day | IM or slow IV | Divided over the day; individualized dosing |
| Acute dystonia | 0.5-1 ampoule (2.5-5 mg) | IM or slow IV | May repeat after 30 min if needed; stop if symptoms resolve during injection |
| Initial dyskinesia | 0.5-1 ampoule (2.5-5 mg) | IM or slow IV | Same protocol as acute dystonia |
Adults
For adult patients with Parkinson's disease requiring parenteral treatment, the typical daily dose is 10-20 mg (2-4 ampoules), distributed throughout the day. Each ampoule contains 1 ml of solution at a concentration of 5 mg/ml. The dose is individualized based on the patient's response and tolerability.
For acute dystonia caused by medications, the initial dose is 2.5-5 mg (half to one ampoule), administered intramuscularly or by slow intravenous injection. Extrapyramidal symptoms may resolve during the intravenous injection itself, in which case the injection should be stopped. If symptoms persist, the prescribed dose may be repeated after 30 minutes.
Children
The use of Akineton injection in children should be determined by a specialist physician. Dosing in pediatric patients is based on age and weight and is generally lower than adult doses. Children may also be more susceptible to the central nervous system stimulating effects of anticholinergic medications, including restlessness and excitation.
Elderly
Elderly patients are often more sensitive to the effects of anticholinergic medications. Age-related changes in renal and hepatic function may affect drug metabolism and elimination. The physician may need to prescribe a lower dose for elderly patients, with careful monitoring for side effects such as confusion, urinary retention, and constipation. The American Geriatrics Society Beers Criteria includes anticholinergic medications on the list of potentially inappropriate medications for older adults due to the risk of cognitive impairment and delirium.
Missed Dose
Since Akineton injection is administered by healthcare professionals in a clinical setting, missed doses are managed by the treating physician. If you have questions about your treatment schedule, consult your healthcare provider.
Overdose
An overdose of Akineton can produce signs and symptoms of anticholinergic toxicity, which may include:
- Confusion, hallucinations, and delirium
- Severe dry mouth and inability to sweat
- Dilated pupils and blurred vision
- Rapid heart rate (tachycardia)
- Elevated body temperature (hyperthermia)
- Urinary retention and constipation
- In severe cases, seizures and loss of consciousness
If you suspect an overdose of Akineton, contact emergency medical services immediately. Treatment is supportive and may include administration of physostigmine (a cholinesterase inhibitor) in severe cases of anticholinergic toxicity, along with cooling measures for hyperthermia and symptomatic treatment of other complications.
What Are the Side Effects of Akineton?
Akineton can cause anticholinergic side effects including dry mouth, nausea, drowsiness, dizziness, memory disturbances, and rapid heart rate. These are classified as rare (up to 1 in 1,000). At higher doses, agitation, hallucinations, and confusion may occur. Very rare effects include allergic reactions, bradycardia (after IV use), and glaucoma.
Like all medications, Akineton can cause side effects, although not everyone experiences them. Side effects are more likely to occur at the beginning of treatment and when doses are increased too rapidly. The anticholinergic mechanism of action is responsible for most adverse effects, as muscarinic receptors are found throughout the body.
It is important to report any unusual or persistent side effects to your healthcare provider. Some side effects may require dose adjustment, while others may be managed with supportive measures. Patients with certain pre-existing conditions (such as prostatic hyperplasia, cognitive impairment, or cardiovascular disease) may be at higher risk for specific side effects.
The frequency of side effects with Akineton has been categorized according to standard medical terminology. Interestingly, most recognized side effects are classified as rare or very rare, which reflects the generally favorable tolerability profile of biperiden when used at appropriate doses under medical supervision.
Rare
- Dry mouth
- Nausea and gastrointestinal discomfort
- Memory disturbances
- Drowsiness and fatigue
- Dizziness
- Temporarily reduced REM sleep
- Tachycardia (rapid heart rate)
- Muscle twitching
Very Rare
- Hypersensitivity reactions and allergic skin rashes
- Reduced sweating
- Headache
- Dyskinesia (difficulty controlling movements)
- Ataxia (difficulty coordinating movements)
- Speech difficulties
- Increased seizure susceptibility
- Nervousness and euphoria
- Difficulty urinating (especially with prostatic hyperplasia)
- Urinary retention
- Constipation
- Bradycardia (slow heart rate, after IV administration)
- Blood pressure decrease (after IV administration)
- Accommodation disturbances and dilated pupils
- Photosensitivity (increased light sensitivity)
- Glaucoma
Not Known
- Parotitis (inflammation of the parotid gland)
High-dose effects
At higher doses, Akineton may produce central nervous system stimulant effects including agitation, anxiety, fear, confusion, hallucinations, and insomnia. These effects are more common in patients with pre-existing psychiatric conditions or cognitive impairment and may require dose reduction. In patients with intellectual disabilities, central stimulant effects are particularly common and may necessitate lower doses.
Cardiovascular effects with IV administration
When Akineton is administered intravenously, there is a risk of transient cardiovascular effects. While tachycardia (rapid heart rate) is the more common anticholinergic cardiac effect, paradoxical bradycardia (slow heart rate) and hypotension (low blood pressure) have been reported very rarely with intravenous use. For this reason, intravenous administration should always be performed slowly and with appropriate monitoring.
Contact your healthcare provider if you experience any severe or persistent side effects, particularly confusion, hallucinations, difficulty urinating, severe constipation, rapid or irregular heartbeat, or visual changes. These may require dose adjustment or alternative treatment.
How Should You Store Akineton?
Store Akineton out of the sight and reach of children. No special storage conditions are required. Do not use after the expiration date printed on the packaging. Unused medication should be disposed of through proper pharmaceutical waste channels.
Proper storage of medications is essential to maintain their efficacy and safety. While Akineton injection is typically stored and managed by healthcare facilities, understanding proper storage conditions is important for ensuring medication quality.
Akineton solution for injection does not require any special storage conditions. However, general good practices for medication storage should be followed:
- Keep out of sight and reach of children at all times
- Check the expiration date before use; the expiration date refers to the last day of the indicated month
- Do not use the medication if you notice any visible changes in appearance, such as discoloration or particles
- Store in the original packaging to protect from light
- Do not mix the injection solution with other medications, as compatibility studies have not been performed
Unused or expired Akineton should not be disposed of via household waste or through the sewage system. Return any unused medication to a pharmacy or follow your local guidelines for pharmaceutical waste disposal. Proper disposal helps protect the environment.
What Does Akineton Contain?
Akineton injection contains biperiden lactate as the active substance, with sodium lactate and water for injections as excipients. Each ampoule contains 1 ml of solution at a concentration of 5 mg/ml. The product is essentially sodium-free (less than 1 mmol per ampoule).
Understanding the full composition of a medication is important for patients with allergies to specific ingredients or those following dietary restrictions.
Active ingredient
The active substance in Akineton injection is biperiden lactate. Biperiden is the pharmacologically active component, while the lactate salt form improves the solubility of the drug in water, making it suitable for injection. Each 1 ml ampoule contains biperiden lactate equivalent to 5 mg of biperiden base.
Excipients (inactive ingredients)
- Sodium lactate: Used as a buffering agent to maintain the appropriate pH of the solution. The sodium content is less than 1 mmol (23 mg) per ampoule, making the product essentially sodium-free.
- Water for injections: The solvent in which the active substance and other excipients are dissolved, meeting pharmaceutical standards for injectable preparations.
Product presentation
Akineton is supplied as a clear solution in glass ampoules. The standard packaging contains 5 ampoules of 1 ml each. Each ampoule is for single use only. The solution should be visually inspected before use and should not be administered if it appears discolored or contains particulate matter.
Frequently Asked Questions About Akineton
Akineton (biperiden) is an anticholinergic medication used to treat two main conditions: Parkinson's disease and drug-induced extrapyramidal symptoms. In Parkinson's disease, it helps control tremor, rigidity, and other motor symptoms by blocking overactive cholinergic pathways in the brain. For extrapyramidal symptoms, particularly acute dystonia and initial dyskinesia caused by antipsychotic medications, Akineton injection provides rapid relief. It is administered by healthcare professionals as an intramuscular or slow intravenous injection.
The onset of action depends on the route of administration. When given intravenously, Akineton acts almost immediately, with extrapyramidal symptoms often resolving during the injection itself. When given intramuscularly, the onset is typically within 10 to 30 minutes. This rapid action makes Akineton injection particularly valuable for treating acute dystonic reactions, which can be distressing and potentially dangerous.
There is limited clinical experience with biperiden use during pregnancy. The safety of Akineton in pregnant women has not been fully established. If you are pregnant or planning to become pregnant, your healthcare provider will carefully assess whether the benefits of treatment outweigh the potential risks. Biperiden also passes into breast milk and can affect the nursing infant, so breastfeeding is not recommended during Akineton treatment.
Akineton (biperiden) and levodopa work through different mechanisms to treat Parkinson's disease. Levodopa is converted to dopamine in the brain, directly replacing the neurotransmitter that is deficient in Parkinson's disease. Akineton, on the other hand, works by blocking acetylcholine receptors, thereby restoring the dopamine-acetylcholine balance. Levodopa is generally considered the gold-standard treatment for Parkinson's disease, while Akineton is used as an adjunctive therapy, particularly for patients with prominent tremor or for treating drug-induced movement disorders.
Tardive dyskinesia is a distinct condition from acute extrapyramidal symptoms, and anticholinergic medications like Akineton can potentially worsen it. Tardive dyskinesia involves involuntary repetitive movements, typically of the face, tongue, and extremities, that develop after prolonged use of dopamine-blocking medications. Unlike acute dystonia, which responds well to anticholinergic treatment, tardive dyskinesia may be aggravated because reducing cholinergic activity further disrupts the already imbalanced neurotransmitter system. Specific treatments for tardive dyskinesia, such as VMAT2 inhibitors (valbenazine, deutetrabenazine), are available instead.
Before receiving Akineton, inform your doctor about: any allergies to biperiden or other medications; history of glaucoma (especially angle-closure type); gastrointestinal conditions such as stenosis or obstruction; prostatic hyperplasia or urinary problems; epilepsy or seizure disorders; heart conditions, especially tachycardia; cognitive impairment or dementia; all other medications you are taking, including over-the-counter drugs and supplements; and whether you are pregnant, breastfeeding, or planning pregnancy.
References
- European Medicines Agency (EMA). Summary of Product Characteristics: Biperiden. European Medicines Agency. Accessed December 2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines - 23rd List (2023). WHO Essential Medicines.
- Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. Journal of Pharmacy and Pharmaceutical Sciences. 1999;2(2):39-46.
- Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry and Clinical Neurosciences. 2014;68(1):37-49.
- American Geriatrics Society. Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2023;71(7):2052-2081.
- National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults: diagnosis and management. NICE Guideline [NG71]. Updated 2024. NICE Guidelines.
- Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683.
- Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurologic Clinics. 2011;29(1):127-148.
- British National Formulary (BNF). Biperiden. BNF Online. Accessed December 2025.
- Müller T. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease. Expert Opinion on Drug Metabolism and Toxicology. 2020;16(5):403-414.
Editorial Team
This article has been written and reviewed by our medical editorial team, consisting of licensed specialist physicians with expertise in neurology, clinical pharmacology, and movement disorders.
All medical content on iMedic is reviewed according to international medical guidelines. We follow the GRADE evidence framework and cite only peer-reviewed sources. Read more about our editorial standards and medical team.